Thiabendazole Treatment of Severe Strongyloidiasis in a Hemodialyzed Patient

T H E PROGRESSION of asymptomatic or mildly sympto-matic Strongyloides stercoralis infection to the often fatal hyperinfected state is a well documented complication of immunosuppression (1). Several deaths have been report-ed in renal transplant recipients given immunosuppres-sive therapy (2). Although thiabendazole is the preferred treatment for strongyloides, the results of conventional 48-h therapy have been disappointing in the hyperinfect-ed patient. Therefore, therapy for as long as 5 days has been recommended (3). Because thiabendazole is rapidly